Great work ISIS!
Maybe the strength on Friday was related to this breaking news:
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes
ISIS had been down significantly Thursday - but as you suggest someone always knows more than the retail investor.
The big diabetes pharmas will go after ISIS now, imo.